Pharmaceutical Planning, Portfolio, Technical Bio-Analysis and Licensing Consultant

Technical Consultant #2226

Pharmaceutical and biotechnology business development and new product planning.
In and Out licensing and strategic partnering.
Commercial analysis and forecasting.
Pharmaceutical life cycle management.
Start-up of Pharmaceuticals, business building in proprietary, generic, and OTC pharmaceuticals and biotechnology, providing modeling and commercial assessments.

Undisclosed Company, Chief Consultant, 2014 - Present

Prepared for pharmaceutical start-up forecast models and commercial assessments for a wide range of potential indications.
Placed clinical trial bio specimens with two companies for biomarker developments.
Developed for emerging biotechnology company: investor and sales presentations, business plan, product brochure, booth design, application briefs and press release for a new product launch.

SPI Pharma, Wilmington, DE, New Product Development and Project Management, 2012 - 2014

Salutria Pharmaceuticals, (Atherogenics, Inc.), Alpharetta, GA, 2004 - 2010

Senior Director Business Development

Spearheaded new product planning, forecasting, financial analysis, portfolio augmentation, biomarker development, and supply chain creation; helped plan and edit clinical protocols.
Held multiple business development roles in an emerging pharmaceutical company.
Completed with team members a $1billion deal with a major global pharmaceutical company.
Searched, found, justified, and took to term sheets and contracts several multi-national cardiovascular and metabolic disease in-licensing opportunities

aaiPharma, Senior Director Business Development, 2002 - 2004

Held broad business development responsibilities in a contract research organization transitioning to an integrated pharmaceutical company.
Generated product life cycle analyses for internal & external clients using drug delivery technologies, physical chemistry techniques, regulatory alternatives, and exclusivity strategies.
Played key role in new product planning for a Japanese joint venture conducting NCE development.

DuPont Merck Pharmaceuticals, 1985 - 2002

Senior Director Business Development and Strategic Planning

Responsible for global cardiovascular new product planning, licensing, and portfolio management.
Implemented innovative market development plan for a new antithrombotic drug.
Improved business intelligence and commercial support for research and development to ensure competitiveness.
Led negotiations and managed due diligence for major late-stage compound; also negotiated favorable terms while surmounting cultural barriers, complex CMC, and exclusivity issues.
Developed opportunity identification process and analyzed over 100 in-licensing candidates.

Director Product Planning

Key member of the Sustiva commercialization team responsible for the "best ever" HIV/AIDS drug launch.
Motivated team to improve forecasts using novel techniques: forecast came within a few percent of actual sales.
Analyzed pricing to find an optimal price that maximized sales without alienating customers.
Organized and built confidence in competent but inexperienced Launch Logistics Team.
Met urgent need for lifesaving drug by shipping largest dollar value in shortest time, by far, of any previous HIV drug - earned corporate and department Marketing Excellence Awards.

Endo Labs, LLC, Director Global Business Development

Responsible for strategic planning and new product generation for generic drug subsidiary.
Created Endo strategic plan: Basis for successful spinout of publicly-traded company with current market cap over $4 billion.
Identified opportunity and negotiated co-development agreement for major pain management product - Opana ER (oxymorphone HCl).
Invented and co-wrote patent, claiming a Product Life Cycle Management Invention.
Structured and negotiated agreements, expanded product line, developed essential customer relationships, and increased revenues - earned DuPont Pharmaceuticals' Summit Award.

Associate Director Business Development

Responsible for planning, licensing and business development.
Co-wrote business plan, structured, and negotiated international generic drug joint venture.
Structured, wrote, and negotiated supply, distribution, and joint development agreements with U.S. and foreign companies that helped establish generic drug business.

Associate Director New Product Planning

Managed portfolio evaluation process and created new product plans.
Created "JiffeVal", an artificial intelligence financial analysis Excel spreadsheet to facilitate financial analyses of pipeline products and in-licensing candidates.
Wrote new product plan convincing management to develop the first angiotensin receptor blocker - accurately forecast Cozaar/Hyzaar worldwide sales peak at $2.5 billion.

Senior Business Analyst

Provided financial analysis and deal-structuring services to medical products licensing group.
Developed novel epidemiology model to estimate market potential for early HIV/AIDS drug.

DuPont, Pigments, Chemicals, and Agricultural Products Departments, 1974 - 1985

Positions Held (of increasing complexity and responsibility)

Business Analyst: Analyzed capital projects and contracts.
Distribution Manager: Managed sales order center distribution group.
Production Supervisor: Supervised pigments manufacturing crew.
Technical Services Chemist: Handled customer complaints and new product development.

Awards

Patents